77.05
+8.56(+12.50%)
Currency In USD
Address
11025 North Torrey Pines Road
La Jolla, CA 92037
United States of America
Phone
858-795-4220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
156
First IPO Date
June 04, 2024
| Name | Title | Pay | Year Born |
| Mr. Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | 1.13M | 1967 |
| Ms. Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President, Chief Financial Officer & Treasurer | 2.19M | 1980 |
| Ms. Leah Pollema J.D. | Vice President, General Counsel & Corporate Secretary | 0 | N/A |
| Dr. Ashraf Amanullah Ph.D. | Executive Vice President & Chief Technical Operations Officer | 0 | 1968 |
| Mr. David J. Matly M.B.A. | President and Chief Commercial & Business Development Officer | 0 | 1986 |
| Dr. Carlos Bais Ph.D. | EVice President & Chief Scientific Officer | 0 | N/A |
| Dr. Josep Garcia Ph.D. | Executive Vice President & Chief Clinical Development Officer | 0 | N/A |
| Ms. Bonne Adams M.B.A. | Vice President of Operations | 0 | 1977 |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.